Prophylactic Treatment Pattern Among the Patient’s Diagnosed with Migraine – An Overview

Background: Migraine is a paroxysmal headache disorder that are characterized by an unilateral p91ain on the head which usually begins at puberty and are much common between 35 to 45 years. The major objective of this review study is to assess the prophylactic treatment pattern among the patients diagnosed with migraine and to provide healthcare professionals with the updated guidance in the use of novel preventive therapy for migraine. Methods: In this systemic review, we identified 89 articles, among which 40 articles was selected, we rejected articles which are not relevant to the study. Search was conducted with no date limits, Abstracts were first selected for full text review and the results were screened for relevance to the review topic. Results:  Patients with migraine require prophylactic therapy to reduce the frequency of migraine attacks. Currently available evidence-based prophylactic treatment options for migraine are topiramate, propranolol and, sumatriptan was the predominant triptan used for acute treatment. New biologics have been developed to target a specific substance in the brain calcitonin gene-related peptide, which plays a key role in migraine pathophysiology recently, 3 new calcitonin gene-related peptide (CGRP) receptor antagonists-erenumab, fremanezumab, and galcanezumab were approved by FDA for prophylactic treatment of migraine. Conclusion: Migraine is the most common neurological disorders. The effective and well tolerated new treatment indicated for prophylaxis may also help for prevention of migraine. A pooled analysis of clinical trial result suggests that, migraine prophylaxis may help to prevent migraine severity, migraine, frequency, migraine chronification, and improve quality of life.